January 2025: The number of pending actions in the GLP-1 RA MDL continues to grow, with 1,331 actions now pending.
Active case
Case Overview
Trulicity® (dulaglutide) lawsuits claim that drug manufacturer Eli Lilly knew or should have known that its product may cause serious health problems but failed to warn consumers about dangerous side effects. Plaintiffs are seeking compensation for injuries related to taking Trulicity, such as gastroparesis and intestinal blockage.
Important Trulicity lawsuit updates
- January 2025: More than 1,200 plaintiffs have filed actions in the GLP-1 RA multidistrict litigation, incluing Trulicity lawsuits, since July 2024. This brings the total number to 1,331.
- December 2024: The MDL will no longer be accepting deep vein thrombosis as an injury. However, Motley Rice will still pursue these cases.
- August 2024: The court addressed how plaintiffs and counsel would share the burden of legal services and case expenses.
- May 2024: Jonathan D. Orent of Motley Rice was appointed co-lead counsel for the Plaintiffs’ Executive Committee (PEC) in the GLP-1 RA multidistrict litigation. Motley Rice attorney Sara Couch was named Chair of the Marketing Discovery Committee for the PEC.
Key takeaways about Trulicity lawsuits
- Eli Lilly, the maker of Trulicity, is facing lawsuits for failing to warn consumers about the drug’s potentially dangerous side effects.
- Trulicity is one of several popular glucagon-like peptide 1 (GLP-1) drugs used for managing diabetes and aiding in weight loss. These medications are associated with an increased risk of gastroparesis and other severe health problems.
- If you or someone you love has a medical condition associated with Trulicity or a similar medication, you may qualify for a diabetes lawsuit. Motley Rice can help you evaluate if you might seek compensation for your injury.
Why is there a lawsuit against Trulicity?
Lawsuits against Eli Lilly allege the manufacturer was aware or should’ve been aware of dangerous side effects associated with Trulicity (dulaglutide) and other GLP-1 RA drugs. Eli Lilly failed to warn consumers, including many who now suffer from severe health conditions, plaintiffs argue.
The Trulicity® lawsuit is a part of a MDL that includes several other Type 2 diabetes medications and prescription weight-loss medications. Eli Lilly also faces litigation concerning Mounjaro® and Zepbound® — brand names for the drug tirzepatide.
In addition, drug manufacturer Novo Nordisk faces lawsuits over injuries that users allege were caused by its GLP-1 medications, including Ozempic® and Wegovy® (both generically called semaglutide) and their predecessors.
What is the Trulicity MDL?
The Trulicity MDL is a mass tort litigation lawsuit. Plaintiffs have brought claims against Eli Lilly and Novo Nordisk for injuries allegedly caused by GLP-1 RA medications.
The MDL names several drugs, including Trulicity, Mounjaro, Ozempic and Wegovy. The lawsuits claim the medications lead to gastrointestinal injuries and other severe side effects. The lawsuits also allege that Eli Lilly and Novo Nordisk didn’t warn patients or prescribing doctors about dangerous side effects. Additionally, the companies are accused of making false and misleading statements about the medications’ safety.
Motley Rice is among the law firms that argued for the creation of the GLP-1 RA multidistrict litigation, which originated in February 2024. The case was initially assigned to U.S. District Judge Gene E.K. Pratter. However, Pratter unexpectedly died in May. In June, U.S. District Judge Karen Marston was named Pratter’s replacement.
As of January 2, 2025, the MDL currently includes more than 1,331 pending actions. Lawyers for the cases expect the lawsuit to eventually contain more than 10,000 claims. Litigation is still in the beginning stages, and new plaintiffs can still join the lawsuit. As of now, all related cases have yet to go to trial or be resolved.
What is multidistrict litigation?
When many plaintiffs have the same complaints against the same defendant, multidistrict litigation (MDL) can lessen the pre-trial burden. With an MDL, pretrial proceedings and discovery happen in one district court after which cases go back to their original district for trial if not settled. Each plaintiff has a lawyer, and each claim may receive its own verdict.
MDLs can be advantageous because they streamline the legal process for both parties and the courts.
Is there a Trulicity class action lawsuit?
No Trulicity class action lawsuits have been filed. Instead, GLP-1 RA medication personal injury cases are being consolidated into an MDL.
Class actions and MDLs differ. With a class action lawsuit, a lawsuit is filed by one or multiple plaintiffs on behalf of a “class” of similarly harmed claimants. Any judgment in the case applies to the entire class, and plaintiffs can’t bring individual lawsuits.
Trulicity and other GLP-1 RA lawsuit plaintiff profiles
Trulicity and other GLP-1 RA lawsuits have been brought by plaintiffs who’ve suffered serious and life-altering injuries.
In one such case, a female plaintiff suffered severe gastrointestinal injuries after taking Ozempic and then Mounjaro to treat Type 2 diabetes. The plaintiff experienced severe stomach pain and vomiting, leading to several emergency room visits and a hospitalization.
In another lawsuit, Motley Rice filed a claim on behalf of a woman who was diagnosed with gastroparesis after taking Wegovy for approximately six months. The woman’s diagnosis came after she was hospitalized for being unable to tolerate food or drink. She continues to have adverse health effects in her daily life.
Many other plaintiffs have filed lawsuits for illnesses suffered in connection with GLP-1 RA drugs. The lawsuits allege that:
- Plaintiffs took Trulicity, Ozempic, Wegovy, Mounjaro or another GLP-1 RA diabetes or weight-loss drug.
- Plaintiffs developed a severe side effect from taking the drug, and the side effect wasn’t included on the medication’s warning label.
- The side effects of these drugs have caused the plaintiffs to suffer physically, mentally, emotionally and financially.
Contact us about a Trulicity lawsuit
Complete this form or call 1.800.768.4026 to contact attorney Sara Couch for more information or to discuss a potential Trulicity claim.
What is Trulicity?
Approved by the U.S. Food and Drug Administration (FDA) in 2014, Trulicity is a GLP-1 RA medication used to treat Type 2 diabetes. In 2020, the FDA also approved the use of Trulicity to reduce cardiovascular events in adults, like stroke and heart attack.
The FDA hasn’t approved Trulicity and Ozempic for weight loss, though some doctors prescribe them for this off-label use. The FDA has approved other GLP-1 RAs, including Wegovy and Saxenda® (liraglutide) for weight reduction.
How does Trulicity work?
Trulicity and other GLP-1 RAs work by mimicking the body’s naturally produced GLP-1 hormone. GLP-1 RA drugs trigger increased insulin production, stop the release of sugar (glucose) into the bloodstream, slow stomach emptying and cause feelings of fullness after eating.
Most GLP-1 RA drugs are injectable medications. Some require daily injections, while others require weekly or twice weekly injections. Trulicity is a once-weekly injectable.
Injuries named in Trulicity side effects lawsuits
Plaintiffs in the Trulicity lawsuit claim they have suffered severe side effects caused by GLP-1 RAs. Many of the medical problems experienced by Trulicity users aren’t on the drug’s warning label or were added after patients started taking the medication.
Vision loss
Studies suggest that taking Trulicity and other GLP-1 agonists increases the risk of nonarteritic anterior ischemic optic neuropathy (NAION) — a type of optic nerve damage and the leading cause of blindness in adults. Trulicity’s warning label doesn’t mention NAION.
The label does warn about the risk of developing diabetic retinopathy (the growth of abnormal blood vessels in the retina). The warning for this condition was not added until February 2020.
Blood clots, deep vein thrombosis (DVT) and pulmonary embolism (PE)
Trulicity’s label doesn’t warn about blood clots. However, some users allege that GLP-1 RA drugs, like Ozempic and Wegovy, cause clots and related health conditions that include:
- Deep vein thrombosis (DVT): DVT is the formation of blood clots in the body’s deep veins, usually in the legs. Symptoms of DVT include leg pain and swelling. The condition can become more serious if the clot breaks loose.
- Pulmonary embolism (PE): DVT can lead to a pulmonary embolism if a blood clot breaks loose and sticks in an artery in the lung, blocking blood flow. A pulmonary embolism is a life-threatening medical emergency.
Gallbladder diseases
Studies suggest that taking GLP-1 RAs significantly increases the risk of gallbladder or biliary diseases. Biliary diseases affect the bile ducts, gallbladder, and systems that produce and transport bile. Symptoms of biliary disease include jaundice (yellowing of the eyes and skin), abdominal pain, fever, fatigue, nausea and vomiting. Trulicity’s label lacks a warning of these dangers.
Gastroenteritis
An inflammation of the stomach and intestines, gastroenteritis causes pain, diarrhea and vomiting. Once again, this side effect isn’t included on Trulicity’s label, but GLP-1 RA lawsuit plaintiffs complain of experiencing this type of gastrointestinal distress while taking these medications.
Gastroparesis/stomach paralysis
Trulicity and other GLP-1 RAs slow the body’s ability to empty the stomach, potentially causing gastroparesis. No cure has been found for this medical condition, which can lead to dehydration, malnutrition and a decreased quality of life. Gastroparesis can also lead to a blockage of undigested food called a bezoar, which can be life-threatening.
Trulicity’s label states under Drug Interactions that it produces delayed gastric emptying, but the label doesn’t warn against the risk of gastroparesis.
Ileus and intestinal obstruction
Ileus is the inability of the intestines to push food and waste out of the body. This condition can lead to intestinal obstruction. Severe complications of ileus and intestinal obstruction include tissue death, infection of the abdominal cavity and perforation of the intestinal wall.
Studies find that patients taking GLP-1 RAs have more than a three-fold increase in intestinal obstruction rate. Yet, Trulicity’s label doesn’t mention ileus or intestinal obstruction as a potential side effect.
Intraoperative pulmonary aspiration
The American Society of Anesthesiologists warns those taking GLP-1 RAs to avoid taking the medicine before surgery. This warning is due to an increased risk of regurgitating and aspirating food in the airways and lungs. Trulicity’s label doesn’t mention this danger.
Listed Trulicity side effects
Among the many side effects that are included on Trulicity’s Warnings and Precautions label are:
- Acute kidney injury: Acute kidney injury (AKI) occurs when the kidneys suddenly can’t filter waste from the blood. AKI replaces the term “acute renal failure.”
- Diabetic retinopathy: This condition causes abnormal blood vessel growth in the retinas, potentially leading to blindness. Warnings for diabetic retinopathy weren’t added to Trulicity’s listed side effects until February 2020.
- Hypersensitivity reactions: A hypersensitivity reaction is a severe immune system response featuring symptoms that often include rash, hives, itching, wheezing and stomach cramps.
- Hypoglycemia: Hypoglycemia occurs when the body’s blood sugar drops below the normal range. Severe side effects of hypoglycemia include changes in speech and vision, confusion, loss of coordination, seizures, and unresponsiveness.
- Pancreatitis: This condition involves the swelling of the pancreas and can result in severe complications, including long-lasting inflammation, pancreatic scarring and permanent pancreatic damage.
- Severe gastrointestinal disease: Symptoms of gastrointestinal disease include stomach pain, bloating, constipation, indigestion, inflammatory bowel disease (IBD) and inflammatory bowel syndrome (IBS).
- Thyroid c-cell tumors: Trulicity contains a boxed warning for thyroid c-cell tumors. This warning is the FDA’s most serious type of warning. Also called medullary thyroid cancer (MTC), this condition is severe and can be deadly.
Trulicity lawsuit updates timeline
01.02.25
January 2025
08.01.24
August 2024
The court established time and expense protocols and a common benefit fund for the GLP-1 RA multidistrict litigation. The court’s case management order outlined how plaintiffs and their attorneys involved in diabetes and weight-loss drug multidistrict litigation (MDL) would share the burden of legal services and expenses.
07.01.24
July 2024
New research came to light associating GLP-1 RA medications with vision loss and blindness. New lawsuits were filed in the MDL over injuries believed to be caused by GLP-1 receptor agonist (RA) drugs, bringing the number of cases to more than 100.
06.01.24
June 2024
U.S. District Judge Karen Marston was appointed to preside over the cases. The appointment was necessary due to the unexpected death of U.S. District Judge Gene E.K. Pratter on May 17.
05.01.24
May 2024
Attorney Jonathan Orent of Motley Rice was named co-lead counsel for the GLP-1 RA multidistrict litigation’s Plaintiff’s Executive Committee (PEC). Motley Rice attorney Sara Couch was named Chair of Marketing Discovery for the PEC.
02.01.24
February 2024
Lawyers, including attorney Jonathan Orent, successfully argued for assigning the diabetes and weight-loss drug MDL to the Eastern District of Pennsylvania.
Frequently asked questions (FAQs) about Trulicity
What are the side effects of using Trulicity?
On and off-label side effects associated with Trulicity and other GLP-1 RA medications include acute kidney injury, pancreatitis and digestive problems. Some of the health problems believed to stem from Trulicity intake may result in permanent and life-altering injuries and death.
On-label side effects of Trulicity include:
- Acute kidney injury
- Diabetic retinopathy
- Hypersensitivity reactions
- Hypoglycemia
- Pancreatitis
- Severe gastrointestinal disease
- Thyroid T-cell tumors
Side effects not listed on Trulicity’s label include:
- Blood clots, deep vein thrombosis (DVT) and pulmonary embolism (PE)
- Gallbladder diseases
- Gastroenteritis
- Gastroparesis/stomach paralysis
- Ileus and intestinal obstruction
- Intraoperative pulmonary aspiration
- Vision loss caused by NAION
Is Trulicity safe?
Trulicity may not be safe for all users, as some patients have experienced severe and deadly side effects.
Trulicity, Ozempic, Wegovy, Mounjaro and other GLP-1 agonists have received FDA approval for the treatment of Type 2 diabetes or weight loss. Approval doesn’t mean the drugs are side-effect-free, though. Some users have experienced severe symptoms.
Anyone considering using a GLP-1 RA should consult their healthcare provider before taking the drug. Patients currently taking these medications should not stop their usage without first consulting their physician.
How do I join the Trulicity lawsuit?
Injured parties can file a Trulicity lawsuit by contacting Motley Rice to learn more about their legal options. Cases are currently being consolidated in U.S. District Court for the Eastern District of Pennsylvania. As of January 2, 2025, more than 1,331 actions are pending, but lawyers expect to add as many as 10,000 claims.
You may be eligible for the MDL if:
- You or someone you love took Trulicity, Ozempic, Wegovy, Mounjaro or another GLP-1 RA agonist medication.
- You or someone you love developed an on- or off-label side effect from the drug, including gastroparesis, acute kidney injury, gallbladder disease, pancreatitis or vision loss.
- You or someone you love encountered financial losses, experienced pain, suffering and inconvenience due to injuries.
If you have questions about the Trulicity MDL and whether you qualify to seek compensation for medical expenses or lost wages, reach out to an attorney at Motley Rice today.
Our medical drug litigation experience
Motley Rice attorneys have been litigating medical drug litigation for decades. Our attorneys have represented thousands of clients harmed by dangerous medications and medical devices. With our legal and scientific knowledge, we can help you navigate even the most complex cases. We will use our resources and case experiences to pursue justice for you or your loved one.
Learn more about our medical drug litigation experience.
Do not stop taking a prescribed medication without first consulting with your doctor. Discontinuing a prescribed medication without your doctor's advice can result in injury or death. Trulicity, Ozempic, Wegovy, Mounjaro Saxenda and Zepbound remain approved by the U.S. Food and Drug Administration.
Important Trulicity lawsuit updates
Key takeaways about Trulicity lawsuits
Why is there a lawsuit against Trulicity?
What is multidistrict litigation?
Is there a Trulicity class action lawsuit?
What is Trulicity?
Injuries named in Trulicity side effects lawsuits
Listed Trulicity side effects
Trulicity lawsuit updates timeline
Frequently asked questions (FAQs) about Trulicity
Our medical drug litigation experience
- Sources
- American College of Gastroenterology. Common Gastrointestinal (GI) Symptoms.
- American Society of Anesthesiologists. Patients Taking Popular Medications for Diabetes and Weight Loss Should Stop Before Elective Surgery, ASA Suggests.
- Cleveland Clinic. Gastroenteritis.
- Cleveland Clinic. GLP-1 Agonists.
- Cleveland Clinic. Medullary Thyroid Cancer (MTC).
- Cornell Law School Legal Information Institute (LII). Class action.
- Cornell Law School Legal Information Institute (LII). Multidistrict litigation.
- Drugs.com. Trulicity FDA Approval History.
- George Washington University Hospital. Biliary Disease.
- Hathaway JT, Shah MP, Hathaway DB, et al. Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide. JAMA Ophthalmol. Published online 2024 July 3.
- He L, Wang J, Ping F, et al. Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials. JAMA Intern Med. 2022 March 28;182(5).
- Johns Hopkins Medicine. Pancreatitis.
- Lu J, Liu H, Zhou Q, Wang MW, Li Z. A potentially serious adverse effect of GLP-1 receptor agonists. Acta Pharm Sin B. 2023 May;13(5).
- Mayo Clinic. Deep vein thrombosis (DVT).
- Mayo Clinic. Diabetic retinopathy.
- Mayo Clinic. Gastroparesis.
- Mayo Clinic. Hypoglycemia.
- Medical News Today. Boxed warnings: What to know.
- Medical News Today. Ozempic vs. Trulicity.
- Medical News Today. What to know about the different types of hypersensitivity reactions.
- National Kidney Foundation. Acute Kidney Injury (AKI).
- Reuters. Ozempic litigation's new judge steps into big battle.
- Trulicity. Managing side effects.
- U.S. Food & Drug Administration (FDA). Trulicity label.
- United States District Court Eastern District of Pennsylvania. CASE MANAGEMENT ORDER NO. 1.
- United States District Court Eastern District of Pennsylvania. CASE MANAGEMENT ORDER NO. 6
- United States District Court Eastern District of Pennsylvania. CASE MANAGEMENT ORDER NO. 17.
- United States District Court Eastern District of Pennsylvania. MDL 3094 In Re: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAS) Products Liability Litigation.
- United States Judicial Panel on Multidistrict Litigation. MDL Statistics Report - Distribution of Pending MDL Dockets by Actions Pending.
- USA Today. Dozens sue saying Ozempic, other weight loss and diabetes drugs cause harmful side effects.
- WebMD. Ileus: What Is It?
Start Your Motley Rice Consultation in Simple Steps
Submit Information
Call us or fill out our online form with the details of your potential case.
Case Review
Our team reviews your information to assess your potential case.
Case Consultation
Talk with us about next steps.